{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:22:50Z","timestamp":1778595770876,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K16451"],"award-info":[{"award-number":["19K16451"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K06782"],"award-info":[{"award-number":["22K06782"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K10075"],"award-info":[{"award-number":["25K10075"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.dmpk.2025.101495","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T19:18:57Z","timestamp":1748287137000},"page":"101495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Continuous exposure to therapeutic drugs doxorubicin and vincristine reduces drug efficacy through transcriptional and post-transcriptional regulation of P-glycoprotein in follicular lymphoma"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4305-8619","authenticated-orcid":false,"given":"Kentaro","family":"Yano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Iwase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuo","family":"Ogihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.dmpk.2025.101495_bib1","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.cmonc.2012.09.015","article-title":"Considerations in the initial management of follicular lymphoma","volume":"9","author":"Nastoupil","year":"2012","journal-title":"Community Oncol"},{"issue":"12","key":"10.1016\/j.dmpk.2025.101495_bib2","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/ajh.26737","article-title":"Follicular lymphoma: 2023 update on diagnosis and management","volume":"97","author":"Jacobsen","year":"2022","journal-title":"Am J Hematol"},{"issue":"23","key":"10.1016\/j.dmpk.2025.101495_bib3","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.dmpk.2025.101495_bib4","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/blood-2018-08-822148","article-title":"How I treat early-relapsing follicular lymphoma","volume":"133","author":"Casulo","year":"2019","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.dmpk.2025.101495_bib5","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","article-title":"Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up","volume":"22","author":"Czuczman","year":"2004","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.dmpk.2025.101495_bib6","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.dmpk.2025.101495_bib7","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/bjc.1994.70","article-title":"The effect of MDR-1 gene expression on outcome in acute myeloblastic leukaemia","volume":"69","author":"Holmes","year":"1994","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.dmpk.2025.101495_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejps.2003.07.003","article-title":"The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability","volume":"21","author":"Chan","year":"2004","journal-title":"Eur J Pharmaceut Sci"},{"issue":"2\u20133","key":"10.1016\/j.dmpk.2025.101495_bib9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0014-5793(98)01663-9","article-title":"Dexamethasone modulation of multidrug transporters in normal tissues","volume":"442","author":"Demeule","year":"1999","journal-title":"FEBS Lett"},{"issue":"46","key":"10.1016\/j.dmpk.2025.101495_bib10","doi-asserted-by":"crossref","first-page":"7068","DOI":"10.3748\/wjg.14.7068","article-title":"Hepatic drug transporters and nuclear receptors: regulation by therapeutic agents","volume":"14","author":"Mottino","year":"2008","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.dmpk.2025.101495_bib11","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/0006-2952(93)90677-O","article-title":"Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P-glycoprotein","volume":"46","author":"Tsuji","year":"1993","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.dmpk.2025.101495_bib12","doi-asserted-by":"crossref","first-page":"E118","DOI":"10.1208\/aapsj070112","article-title":"Role of the breast cancer resistance protein (ABCG2) in drug transport","volume":"7","author":"Mao","year":"2005","journal-title":"AAPS J"},{"issue":"4","key":"10.1016\/j.dmpk.2025.101495_bib13","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3109\/03602532.2015.1105253","article-title":"MRP1 and its role in anticancer drug resistance","volume":"47","author":"Lu","year":"2015","journal-title":"Drug Metab Rev"},{"issue":"5","key":"10.1016\/j.dmpk.2025.101495_bib14","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ijc.21013","article-title":"MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid","volume":"116","author":"Huisman","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.dmpk.2025.101495_bib15","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.biopha.2018.03.088","article-title":"MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT\/NF-\u03baB signaling pathway in breast cancer","volume":"102","author":"Xie","year":"2018","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.dmpk.2025.101495_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/ijc.21094","article-title":"Doxorubicin induces expression of multidrug resistance-associated protein 1 in human small cell lung cancer cell lines by the c-jun N-terminal kinase pathway","volume":"117","author":"Shinoda","year":"2005","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.dmpk.2025.101495_bib17","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ijc.10246","article-title":"Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin","volume":"98","author":"Tada","year":"2002","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.dmpk.2025.101495_bib18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood.V99.2.641","article-title":"P-glycoprotein-actin association through ERM family proteins: a role in P-glycoprotein function in human cells of lymphoid origin","volume":"99","author":"Luciani","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.dmpk.2025.101495_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1248\/bpb.b20-00693","article-title":"Functional alterations of multidrug resistance-associated proteins 2 and 5, and breast cancer resistance protein upon snail-induced epithelial-mesenchymal transition in HCC827 cells","volume":"44","author":"Yano","year":"2021","journal-title":"Biol Pharm Bull"},{"issue":"11","key":"10.1016\/j.dmpk.2025.101495_bib20","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.3390\/cancers12113352","article-title":"Physiological roles of ERM proteins and transcriptional regulators in supporting membrane expression of efflux transporters as factors of drug resistance in cancer","volume":"12","author":"Ogihara","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.dmpk.2025.101495_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-89931-9","article-title":"The inhibition of ABCB1\/MDR1 or ABCG2\/BCRP enables doxorubicin to eliminate liver cancer stem cells","volume":"11","author":"Yin","year":"2021","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.dmpk.2025.101495_bib22","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.febslet.2005.12.036","article-title":"Substrate recognition and transport by multidrug resistance protein 1 (ABCC1)","volume":"580","author":"Deeley","year":"2006","journal-title":"FEBS Lett"},{"issue":"11","key":"10.1016\/j.dmpk.2025.101495_bib23","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/sj.cgt.7701082","article-title":"Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs","volume":"14","author":"Folmer","year":"2007","journal-title":"Cancer Gene Ther"},{"issue":"11","key":"10.1016\/j.dmpk.2025.101495_bib24","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.bcp.2005.03.001","article-title":"Reversal of in vitro cellular MRP1 and MRP2 mediated vincristine resistance by the flavonoid myricetin","volume":"69","author":"van Zanden","year":"2005","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"10.1016\/j.dmpk.2025.101495_bib25","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1124\/dmd.114.058248","article-title":"The need for human breast cancer resistance protein substrate and inhibition evaluation in drug discovery and development: why, when, and how?","volume":"42","author":"Poirier","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmpk.2025.101495_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41514-024-00135-7","article-title":"A review of the pathophysiological mechanisms of doxorubicin-induced cardiotoxicity and aging","volume":"10","author":"Linders","year":"2024","journal-title":"NPJ Aging."},{"issue":"46","key":"10.1016\/j.dmpk.2025.101495_bib27","doi-asserted-by":"crossref","first-page":"29085","DOI":"10.1016\/S0021-9258(19)62016-8","article-title":"GS-X pump is functionally overexpressed in cis-diamminedichloroplatinum (II)-resistant human leukemia HL-60 cells and down-regulated by cell differentiation","volume":"269","author":"Ishikawa","year":"1994","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.dmpk.2025.101495_bib28","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1248\/bpb.b20-00014","article-title":"Total saponins from Paris forrestii reverse multidrug resistance of MCF-7\/ADM cells by suppression of P-gp via ERK signaling pathway","volume":"43","author":"Chai","year":"2020","journal-title":"Biol Pharm Bull"},{"issue":"8","key":"10.1016\/j.dmpk.2025.101495_bib29","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.tiv.2014.06.004","article-title":"Multi-drug resistance in a canine lymphoid cell line due to increased P-glycoprotein expression, a potential model for drug-resistant canine lymphoma","volume":"28","author":"Zandvliet","year":"2014","journal-title":"Toxicol Vitro"},{"key":"10.1016\/j.dmpk.2025.101495_bib30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1471-2407-8-51","article-title":"Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML)","volume":"8","author":"Tang","year":"2008","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.dmpk.2025.101495_bib31","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.exphem.2011.01.013","article-title":"Upregulation of mdr1 gene is related to activation of the MAPK\/ERK signal transduction pathway and YB-1 nuclear translocation in B-cell lymphoma","volume":"39","author":"Shen","year":"2011","journal-title":"Exp Hematol"},{"issue":"3","key":"10.1016\/j.dmpk.2025.101495_bib32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1023\/A:1006138803392","article-title":"Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells","volume":"53","author":"Daschner","year":"1999","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.dmpk.2025.101495_bib33","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3892\/ijo.4.6.1237","article-title":"P-glycoprotein expression in non-hodgkins-lymphoma","volume":"4","author":"West","year":"1994","journal-title":"Int J Oncol"},{"issue":"1","key":"10.1016\/j.dmpk.2025.101495_bib34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1200\/JCO.1991.9.1.17","article-title":"P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil","volume":"9","author":"Miller","year":"1991","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.dmpk.2025.101495_bib35","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1124\/mol.112.081844","article-title":"MicroRNA-145 post-transcriptionally regulates the expression and function of P-glycoprotein in intestinal epithelial cells","volume":"83","author":"Ikemura","year":"2013","journal-title":"Mol Pharmacol"},{"issue":"7254","key":"10.1016\/j.dmpk.2025.101495_bib36","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature08199","article-title":"Modulation of microRNA processing by p53","volume":"460","author":"Suzuki","year":"2009","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.dmpk.2025.101495_bib37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1248\/bpb.b17-00725","article-title":"Advances in studies of P-glycoprotein and its expression regulators","volume":"41","author":"Yano","year":"2018","journal-title":"Biol Pharm Bull"},{"issue":"4","key":"10.1016\/j.dmpk.2025.101495_bib38","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/jphp.13225","article-title":"Regulation of breast cancer resistance protein and P-glycoprotein by ezrin, radixin and moesin in lung, intestinal and renal cancer cell lines","volume":"72","author":"Yano","year":"2020","journal-title":"J Pharm Pharmacol"},{"issue":"9","key":"10.1016\/j.dmpk.2025.101495_bib39","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.xphs.2017.04.003","article-title":"Gastrointestinal hormone cholecystokinin increases P-glycoprotein membrane localization and transport activity in caco-2 cells","volume":"106","author":"Yano","year":"2017","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.dmpk.2025.101495_bib40","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/jps.23637","article-title":"Contribution of radixin to P-glycoprotein expression and transport activity in mouse small intestine in vivo","volume":"102","author":"Yano","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.dmpk.2025.101495_bib41","series-title":"TREANDA\u00ae product monograph","year":"2012"},{"issue":"3","key":"10.1016\/j.dmpk.2025.101495_bib42","first-page":"213","article-title":"Establishment and characteristics of a novel mantle cell lymphoma-derived cell line and a bendamustine-resistant subline","volume":"15","author":"Takimoto-Shimomura","year":"2018","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.dmpk.2025.101495_bib43","first-page":"278","article-title":"In vitro and ex vivo activity of SDX-105 (bendamustine) in drug-resistant lymphoma cells","volume":"45","author":"Leoni","year":"2004","journal-title":"Proc Am Assoc Cancer Res"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436725004458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436725004458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:01:21Z","timestamp":1778594481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436725004458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":43,"alternative-id":["S1347436725004458"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2025.101495","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Continuous exposure to therapeutic drugs doxorubicin and vincristine reduces drug efficacy through transcriptional and post-transcriptional regulation of P-glycoprotein in follicular lymphoma","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2025.101495","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101495"}}